Globus Medical, Inc. (GMED) News
Filter GMED News Items
GMED News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
GMED News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest GMED News From Around the Web
Below are the latest news stories about GLOBUS MEDICAL INC that investors may wish to consider to help them evaluate GMED as an investment opportunity.
Outlook For These Biotechs Brightens As FDA Ushers In New Rules For SectorBiotech stock GeneDx broke out after the FDA issued its first AI rules for medical devices. Globus Medical and GeneDx are in buy zones. |
These Oil And Gas Names Hit Highs As Energy Prices JumpTwo oil and gas stocks hit 52-week highs as energy prices popped Friday. The stocks are in buy zones while a medical device stock climbed. |
GMED Stock Rides on NuVasive Synergy Benefits Amid Macro IssuesGlobus Medical is seeing notable gains across its product portfolio in expandables, biologics, MIS screws, 3D printed implants and cervical offerings. |
Globus Medical upgraded to Neutral from Underperform at BofABofA analyst Craig Bijou upgraded Globus Medical (GMED) to Neutral from Underperform with a price target of $97, up from $80, after the company preannounced Q4 revenue that was 3% above the Street view. This was “an important quarter” as it marks a year since the salesforce integration began, notes the analyst, who says Globus has managed the integration of NuVasive better than the firm expected. BofA now sees less risk of dis-synergies moving forward, the analyst added. Published first on TheFl |
Globus Medical Reports Preliminary Record Fourth Quarter and Full Year Sales ResultsAUDUBON, Pa., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal solutions company, today announced preliminary unaudited sales results for the fourth quarter and full year ending December 31, 2024. The company anticipates fourth quarter 2024 sales of approximately $657.0 million, an increase of 6.6 percent over the fourth quarter 2023 on an as-reported basis. Full year 2024 sales are expected to be approximately $2.52 billion, an increase of 60.6 perc |
Are You a Momentum Investor? This 1 Stock Could Be the Perfect PickThe Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage. |
Globus Medical Stock Revs Up For Next Move After 70% RunThis leading medical device maker is showing constructive action in a flat base and setting up for its next move. |
Why Globus Medical (GMED) is a Top Growth Stock for the Long-TermWhether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service. |
4 Healthcare Stocks Rising More Than 50% in 2024 With Room to GrowMedical stocks are expected to reap the benefits of affordable health insurance plans, rising surgeries and widespread adoption of telehealth services in the days ahead. However, inflation and supply-chain woes may act as spoilsport. |
Reasons to Add GMED Stock to Your Portfolio Right NowGlobus Medical's synergistic merger with NuVasive and a strong liquidity position bring optimism to investors. |